First patients receive experimental pill targeting Hard-to-Treat cancers
Disease control
Recruiting now
This is the first-ever human study of an experimental pill called PLX-61639. It is being tested in adults with advanced cancers that have a specific genetic flaw (SMARCA4 mutation) and have stopped responding to standard treatments. The main goals are to find a safe dose and see …
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC